Kiebish 2013 J Lipid Res: Difference between revisions
No edit summary |
Beno Marija (talk | contribs) No edit summary ย |
||
(18 intermediate revisions by 6 users not shown) | |||
Line 1: | Line 1: | ||
{{Publication | {{Publication | ||
|title=Kiebish MA, Yang K, Liu X, Mancuso DJ, Guan S, Zhao Z, Sims HF, Cerqua R, Cade WT, Han X, Gross RW (2013) Dysfunctional cardiac mitochondrial bioenergetic, lipidomic, and signaling in a murine model of Barth syndrome. J Lipid Res | |title=Kiebish MA, Yang K, Liu X, Mancuso DJ, Guan S, Zhao Z, Sims HF, Cerqua R, Cade WT, Han X, Gross RW (2013) Dysfunctional cardiac mitochondrial bioenergetic, lipidomic, and signaling in a murine model of Barth syndrome. J Lipid Res 54:1312-25. | ||
|info=[http://www.ncbi.nlm.nih.gov/pubmed/23410936 PMID: 23410936 Open Access] | |info=[http://www.ncbi.nlm.nih.gov/pubmed/23410936 PMID: 23410936 Open Access] | ||
|authors=Kiebish MA, Yang K, Liu X, Mancuso DJ, Guan S, Zhao Z, Sims HF, Cerqua R, Cade WT, Han X, Gross RW | |authors=Kiebish MA, Yang K, Liu X, Mancuso DJ, Guan S, Zhao Z, Sims HF, Cerqua R, Cade WT, Han X, Gross RW | ||
|year=2013 | |year=2013 | ||
|journal=J Lipid Res | |journal=J Lipid Res | ||
|abstract=Barth syndrome is a complex metabolic disorder caused by mutations in the mitochondrial transacylase Tafazzin. Recently, an inducible Tafazzin shRNA knockdown mouse model was generated to deconvolute the complex bioenergetic phenotype of this disease. To investigate the underlying cause of hemodynamic dysfunction in Barth syndrome, we interrogated the cardiac structural and signaling lipidome of this mouse model as well as its myocardial bioenergetic phenotype. A decrease in the distribution of cardiolipin molecular species and robust increases in monolysocardiolipin and dilysocardiolipin were demonstrated. Additionally, the contents of choline and ethanolamine glycerophospholipid molecular species containing precursors for lipid signaling at the sn-2 position were altered. Lipidomic analyses revealed specific dysregulation of HETEs, prostanoids, as well as oxidized linoleic and docosahexaenoic metabolites. Bioenergetic interrogation uncovered differential substrate utilization as well as deceases in Complex III and | |abstract=Barth syndrome is a complex metabolic disorder caused by mutations in the mitochondrial transacylase Tafazzin. Recently, an inducible Tafazzin shRNA knockdown mouse model was generated to deconvolute the complex bioenergetic phenotype of this disease. To investigate the underlying cause of hemodynamic dysfunction in Barth syndrome, we interrogated the cardiac structural and signaling lipidome of this mouse model as well as its myocardial bioenergetic phenotype. A decrease in the distribution of cardiolipin molecular species and robust increases in monolysocardiolipin and dilysocardiolipin were demonstrated. Additionally, the contents of choline and ethanolamine glycerophospholipid molecular species containing precursors for lipid signaling at the sn-2 position were altered. Lipidomic analyses revealed specific dysregulation of HETEs, prostanoids, as well as oxidized linoleic and docosahexaenoic metabolites. Bioenergetic interrogation uncovered differential substrate utilization as well as deceases in Complex III and CV activities. Transgenic expression of cardiolipin synthase or iPLA2ฮณ ablation in Tafazzin deficient mice did not rescue the observed phenotype. These results underscore the complex nature of alterations in cardiolipin metabolism mediated by Tafazzin loss of function. Collectively, we identified specific lipidomic, bioenergetic and signaling alterations in a murine model that parallel those of Barth syndrome thereby providing novel insights into the pathophysiology of this debilitating disease. | ||
|keywords=Lipidome; Cardiolipin; Tafazzin; Phospholipase | |keywords=Lipidome; Cardiolipin; Tafazzin; Phospholipase; Cardiolipin synthase; Barth syndrome | ||
|mipnetlab=US MO St Louis Gross RW | |mipnetlab=US MO St Louis Gross RW | ||
}} | }} | ||
{{Labeling | {{Labeling | ||
| | |area=Respiration, nDNA;cell genetics, Genetic knockout;overexpression, mt-Medicine | ||
|organism=Mouse | |organism=Mouse | ||
|tissues=Heart | |tissues=Heart | ||
|preparations=Isolated | |preparations=Isolated mitochondria | ||
|enzymes=Complex III, Complex V; ATP | |enzymes=Complex I, Complex II;succinate dehydrogenase, Complex III, Complex IV;cytochrome c oxidase, Complex V;ATP synthase | ||
|injuries=Mitochondrial disease | |||
|diseases=Other | |||
|couplingstates=LEAK, OXPHOS | |||
|pathways=F, N, S, NS | |||
|instruments=Oxygraph-2k | |||
}} | }} |
Latest revision as of 17:51, 7 November 2016
Kiebish MA, Yang K, Liu X, Mancuso DJ, Guan S, Zhao Z, Sims HF, Cerqua R, Cade WT, Han X, Gross RW (2013) Dysfunctional cardiac mitochondrial bioenergetic, lipidomic, and signaling in a murine model of Barth syndrome. J Lipid Res 54:1312-25. |
Kiebish MA, Yang K, Liu X, Mancuso DJ, Guan S, Zhao Z, Sims HF, Cerqua R, Cade WT, Han X, Gross RW (2013) J Lipid Res
Abstract: Barth syndrome is a complex metabolic disorder caused by mutations in the mitochondrial transacylase Tafazzin. Recently, an inducible Tafazzin shRNA knockdown mouse model was generated to deconvolute the complex bioenergetic phenotype of this disease. To investigate the underlying cause of hemodynamic dysfunction in Barth syndrome, we interrogated the cardiac structural and signaling lipidome of this mouse model as well as its myocardial bioenergetic phenotype. A decrease in the distribution of cardiolipin molecular species and robust increases in monolysocardiolipin and dilysocardiolipin were demonstrated. Additionally, the contents of choline and ethanolamine glycerophospholipid molecular species containing precursors for lipid signaling at the sn-2 position were altered. Lipidomic analyses revealed specific dysregulation of HETEs, prostanoids, as well as oxidized linoleic and docosahexaenoic metabolites. Bioenergetic interrogation uncovered differential substrate utilization as well as deceases in Complex III and CV activities. Transgenic expression of cardiolipin synthase or iPLA2ฮณ ablation in Tafazzin deficient mice did not rescue the observed phenotype. These results underscore the complex nature of alterations in cardiolipin metabolism mediated by Tafazzin loss of function. Collectively, we identified specific lipidomic, bioenergetic and signaling alterations in a murine model that parallel those of Barth syndrome thereby providing novel insights into the pathophysiology of this debilitating disease. โข Keywords: Lipidome; Cardiolipin; Tafazzin; Phospholipase; Cardiolipin synthase; Barth syndrome
โข O2k-Network Lab: US MO St Louis Gross RW
Labels: MiParea: Respiration, nDNA;cell genetics, Genetic knockout;overexpression, mt-Medicine
Pathology: Other
Stress:Mitochondrial disease
Organism: Mouse
Tissue;cell: Heart
Preparation: Isolated mitochondria
Enzyme: Complex I, Complex II;succinate dehydrogenase, Complex III, Complex IV;cytochrome c oxidase, Complex V;ATP synthase
Coupling state: LEAK, OXPHOS Pathway: F, N, S, NS HRR: Oxygraph-2k